Department of Biomedical Engineering, Cleveland Clinic, Cleveland, OH 44195, USA.
Osteoarthritis Cartilage. 2010 Mar;18(3):455-63. doi: 10.1016/j.joca.2009.10.014. Epub 2009 Nov 4.
Glucosamine has been previously shown to suppress cartilage aggrecan catabolism in explant cultures. We determined the effect of glucosamine on ADAMTS5 (a disintegrin-like and metalloprotease domain (reprolysin type) with thrombospondin type-1 motifs 5), a major aggrecanase in osteoarthritis, and investigated a potential mechanism underlying the observed effects.
HEK293F and CHO-K1 cells transiently transfected with ADAMTS5 cDNA were treated with glucosamine or the related hexosamine mannosamine. Glucosamine effects on FURIN transcription were determined by quantitative RT-PCR. Effects on furin-mediated processing of ADAMTS5 zymogen, and aggrecan processing by glucosamine-treated cells, were determined by western blotting. Post-translational modification of furin and N-glycan deficient furin mutants generated by site-directed mutagenesis was analyzed by western blotting, and the mutants were evaluated for their ADAMTS5 processing ability in furin-deficient CHO-RPE.40 cells.
Ten mM glucosamine and 5-10mM mannosamine reduced excision of the ADAMTS5 propeptide, indicating interference with the propeptide excision mechanism, although mannosamine compromised cell viability at these doses. Although glucosamine had no effect on furin mRNA levels, western blot of furin from glucosamine-treated cells suggested altered post-translational modification. Glucosamine treatment led to decreased glycosylation of cellular furin, with reduced furin autoactivation as the consequence. Recombinant furin treated with peptide N-glycanase F had reduced activity against a synthetic peptide substrate. Indeed, site-directed mutagenesis of two furin N-glycosylation sites, Asn(387) and Asn(440), abrogated furin activation and this mutant was unable to rescue ADAMTS5 processing in furin-deficient cells.
Ten mM glucosamine reduces excision of the ADAMTS5 propeptide via interference with post-translational modification of furin and leads to reduced aggrecanase activity of ADAMTS5.
先前的研究表明,氨基葡萄糖可抑制软骨聚集蛋白聚糖在组织培养中的分解代谢。我们确定了氨基葡萄糖对 ADAMTS5(一种在骨关节炎中主要的聚集蛋白聚糖酶,具有解整合素样金属蛋白酶域(类糜蛋白酶)和血小板反应蛋白-1 基序 5)的影响,并研究了观察到的影响的潜在机制。
用 ADAMTS5 cDNA 瞬时转染的 HEK293F 和 CHO-K1 细胞用氨基葡萄糖或相关的己糖胺甘露胺处理。通过定量 RT-PCR 确定氨基葡萄糖对 FURIN 转录的影响。通过 Western blot 确定氨基葡萄糖处理细胞对 ADAMTS5 酶原的弗林介导的加工以及对聚集蛋白聚糖的加工的影响。通过 Western blot 分析弗林的翻译后修饰和通过定点突变产生的 N-糖基化缺陷弗林突变体,并在缺乏弗林的 CHO-RPE.40 细胞中评估突变体对 ADAMTS5 加工的能力。
10mM 氨基葡萄糖和 5-10mM 甘露胺减少了 ADAMTS5 前肽的切除,表明干扰了前肽切除机制,尽管这些剂量的甘露胺会损害细胞活力。尽管氨基葡萄糖对 FURIN mRNA 水平没有影响,但用氨基葡萄糖处理细胞的弗林的 Western blot 表明发生了翻译后修饰的改变。氨基葡萄糖处理导致细胞弗林的糖基化减少,导致弗林的自动激活减少。用肽 N-糖基酶 F 处理的重组弗林对合成肽底物的活性降低。事实上,两个弗林 N-糖基化位点(Asn(387)和 Asn(440))的定点突变消除了弗林的激活,并且该突变体无法在缺乏弗林的细胞中拯救 ADAMTS5 的加工。
10mM 氨基葡萄糖通过干扰弗林的翻译后修饰减少 ADAMTS5 前肽的切除,并导致 ADAMTS5 聚集蛋白聚糖酶活性降低。